5-aminopyrazoles useful as tyrosine kinase inhibitors
US5922741A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 22, 1997 |
| Grant date | Jul 13, 1999 |
| Priority date | — |
| Expiry date | Apr 22, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of general formula (1) are described: ##STR1## wherein Ar is an optionally substituted aromatic or heteroaromatic group; PA1 X.sup.1 is an oxygen or sulphur atom; PA1 R.sup.1 is a hydrogen atom or a methyl group; PA1 R.sup.2 is a hydrogen atom or a group --Alk.sup.1 or --X.sup.2 Alk.sup.1 where Alk.sup.1 is an optionally substituted aliphatic or heteroaliphatic group and X.sup.2 is a --C(O)--, --C(S)--, or --S(O).sub.n group where n is an integer 1 or 2; PA1 R.sup.3 is a hydrogen atom or a group --Alk.sup.2, where Alk.sup.2 is as defined for Alk.sup.1 !, --X.sup.2 Alk.sup.2, --Ar.sup.1 where Ar.sup.1 is an optionally substituted aromatic or heteroaromatic group!, --Alk.sup.2 Ar.sup.1, or --X.sup.2 Alk.sup.2 Ar.sup.1 ; PA1 and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective inhibitors of the protein tyrosine kinase p56.sup.lck and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate p56.sup.lck activity is believed to have a role.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.